2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157461
    Glycation-IN-1 3023711-86-3 98%
    Glycation-IN-1 (Compound 3) is an inhibitor of glycosylation reactions, which has a strong inhibitory effect on the synthesis of initial, intermediate, and final products of glycosylation reactions. Glycion-IN-1 can be used in the research of various chronic diseases, such as diabetes, immune inflammation, cardiovascular diseases and neurodegenerative diseases.
    Glycation-IN-1
  • HY-157546
    VEGFR-2-IN-40 98%
    VEGFR-2-IN-40 is a VEGFR-2 inhibitor. VEGFR-2-IN-40 boosts early and late apoptosis. VEGFR-2-IN-40 decreases the levels immunomodulatory proteins TNF-α and IL-6 while showing a four-fold rise in an apoptotic marker caspase-3.
    VEGFR-2-IN-40
  • HY-157554
    ZM640 98%
    ZM640 is a NLRP3 inhibitor. ZM640 enhances IL-1β release mediated by NLRP3 inflammasome activation in THP-1 cells. ZM640 shows low cytotoxicity.
    ZM640
  • HY-157751
    RIPK1-IN-21 3016304-64-3 98%
    RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases.
    RIPK1-IN-21
  • HY-157766
    FAAH/TRPV1 blocker-1 98%
    FAAH/TRPV1 blocker-1 (compound 2R) is a dual FAAH/TRPV1 blocker, with IC50 of 0.12 and 94.9 μM, respectively. FAAH/TRPV1 blocker-1 plays an important role in analgesic and anti-inflammatory research.
    FAAH/TRPV1 blocker-1
  • HY-157809
    Anti-inflammatory agent 74 98%
    Anti-inflammatory agent 74 (B5) is an anti-inflammatory agent that can inhibit NO, IL-6, and TNF-α, with IC50 values of 10.88 μM and 4.93 μM for NO and IL-6, respectively. Anti-inflammatory agent 74 alleviates acute lung injury (ALI) by regulating inflammatory mediators and inhibiting the MAPK and NF-κB signaling pathways.
    Anti-inflammatory agent 74
  • HY-157822
    Galectin-8-IN-2 1044566-24-6 98%
    Galectin-8-IN-2 (Compound 10) is a galectin-8N inhibitor.
    Galectin-8-IN-2
  • HY-157874
    Eoxin A4 81918-96-9
    Eoxin A4 (14,15-Leukotriene A4) is an Arachidonic acid (HY-109590) metabolite. Eoxin A4 forms via the 15-lipoxygenase pathway.
    Eoxin A4
  • HY-157928
    Keap1-Nrf2-IN-18 98%
    Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structure−activity relationship (SAR) study (KD = 0.0029 μM).
    Keap1-Nrf2-IN-18
  • HY-157929
    Keap1-Nrf2-IN-19 98%
    Keap1-Nrf2-IN-19 (compound 33) is an oral active Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with the Kd value of 0.0014 μM. Keap1-Nrf2-IN-19 exhibits less than 50% inhibition at 30 μM against hERG and 10 μM against CYPs.
    Keap1-Nrf2-IN-19
  • HY-157961
    E-5531 162679-36-9
    E-5531 is an endotoxin antagonist. E-5531 quickly becomes inactive after binding with HDL. E-5531 can block the Toll like receptor 4 (TLR4) signaling pathway. E-5531 can be used for the study of endotoxemia and septic shock.
    E-5531
  • HY-157963
    RIPK1-IN-23 3031534-16-1 98%
    RIPK1-IN-23 (compound 19) is a RIPK1 inhibitor with potent anti-necroptotic effects in HT-29 cells (EC50 of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities.
    RIPK1-IN-23
  • HY-157995
    Dyrk1A-IN-7 98%
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases.
    Dyrk1A-IN-7
  • HY-158022
    CTSL/CAPN1-IN-1 98%
    CTSL/CAPN1-IN-1 (compound 14a) is an oral active CTSL and CAPN1 inhibitor with the IC50  values of 3.34 nM and 375.1 nM for CTSL and CAPN1, respectively. CTSL/CAPN1-IN-1 shows anticoronaviral activity and anti-inflammatory effect.
    CTSL/CAPN1-IN-1
  • HY-158036
    PROTAC STING Degrader-2 3023095-61-3 98%
    PROTAC STING Degrader-2 is a STING PROTAC degrader with a DC50 of 0.53 μM. PROTAC STING Degrader-2 reduces the phosphorylation levels of TBK1 and IRF3. PROTAC STING Degrader-2 decreases the mRNA expression levels of IFN-β, CXCL10 and TNF-α, and blocks luciferase secretion. PROTAC STING Degrader-2 can be used in the research of autoimmune diseases.
    PROTAC STING Degrader-2
  • HY-158048
    UNC9036 3094059-54-5 98%
    UNC9036 is a PROTAC-based STING degrader, with a DC50 of 227 nM. UNC9036-mediated STING degradation is proteasome and VHL dependent (Structure Note: Red, STING agonist diABZI (HY-112921A); Blue, VHL ligand VH032 (HY-120217); Black, linker).
    UNC9036
  • HY-158058
    WYJ-2 3029403-05-9 98%
    WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC).
    WYJ-2
  • HY-158093
    NIC-12 2409826-23-7 98%
    NIC-12 is a potent NLRP3 inhibitor. NIC-12 selectively reduces circulating IL-1ß levels in the LPS-endotoxemia mice model. NIC-12 inhibits NLRP3 inflammasome activation in mouse macrophages.
    NIC-12
  • HY-158111
    NLRP3-IN-34 1392502-55-4 98%
    NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis.
    NLRP3-IN-34
  • HY-158120
    LasR agonist 1 98%
    LasR agonist 1 (9) is a LasR agonist, with an EC50 of 0.7 μM. Used for P. aeruginosa research.
    LasR agonist 1
Cat. No. Product Name / Synonyms Application Reactivity